U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C18H27NO2.C2H6O6S2
Molecular Weight 769.02
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARAMIPHEN EDISYLATE

SMILES

OS(=O)(=O)CCS(O)(=O)=O.CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2.CCN(CC)CCOC(=O)C3(CCCC3)C4=CC=CC=C4

InChI

InChIKey=BANIDACEBXZGNK-UHFFFAOYSA-N
InChI=1S/2C18H27NO2.C2H6O6S2/c2*1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16;3-9(4,5)1-2-10(6,7)8/h2*5-7,10-11H,3-4,8-9,12-15H2,1-2H3;1-2H2,(H,3,4,5)(H,6,7,8)

HIDE SMILES / InChI
Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: voltage-gated Na⁺ currents
52.1 µM [IC50]
Target ID: P11229
Gene ID: 1128.0
Gene Symbol: CHRM1
Target Organism: Homo sapiens (Human)
1.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SKF TUSS-ORNADE

Approved Use

Unknown
Primary
parpanit

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 30
Health Status: healthy
Condition: cough
Age Group: adult
Sex: unknown
Population Size: 30
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (3 patients)
Dizziness (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 2 patients
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 30
Health Status: healthy
Condition: cough
Age Group: adult
Sex: unknown
Population Size: 30
Sources:
Nausea 3 patients
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
n = 30
Health Status: healthy
Condition: cough
Age Group: adult
Sex: unknown
Population Size: 30
Sources:
PubMed

PubMed

TitleDatePubMed
Anti-nicotinic properties of anticholinergic antiparkinson drugs.
1998 Nov
Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction.
2002 May
Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction.
2003 Sep
Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning.
2007 May
Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman.
2008 Feb
Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen.
2008 Feb 15
Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.
2008 Jun
Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties.
2008 Oct 15
Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment.
2010 Dec
Roles of perirhinal and posterior piriform cortices in control and generation of seizures: a microinfusion study in rats exposed to soman.
2010 Jan
Isobolographic analysis of caramiphen and lidocaine on spinal anesthesia in rats.
2010 Jan 18
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats].
2010 May
Antidepressant-like effect of centrally acting non-narcotic antitussive caramiphen in a forced swimming test.
2010 Sep 13
The anticholinergic and antiglutamatergic drug caramiphen reduces seizure duration in soman-exposed rats: synergism with the benzodiazepine diazepam.
2012 Mar 15
Patents

Sample Use Guides

2.5 to 6.0 mg/kg
Route of Administration: Intravenous
It was investigated the effect of caramiphen (300uM) on voltage-gated sodium channels in differentiated neuronal NG108-15 cells. Caramiphen exhibited a milder state-dependence of block (IC₅₀ of 52.1 and 99.5 µM at holding potentials of -70 and -100 mV, respectively).
Name Type Language
CARAMIPHEN EDISYLATE
GREEN BOOK   VANDF  
Common Name English
Caramiphen edisilate [WHO-DD]
Common Name English
CARAMIPHEN EDISILATE
MART.   WHO-DD  
Common Name English
CARAMIPHEN EDISYLATE [VANDF]
Common Name English
CARAMIPHEN ETHANEDISULFONATE
MI  
Common Name English
CARAMIPHEN EDISYLATE [GREEN BOOK]
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 1-PHENYL-, 2-(DIETHYLAMINO)ETHYL ESTER, 1,2-ETHANEDISULPHONATE (2:1)
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 1-PHENYL-, 2-(DIETHYLAMINO)ETHYL ESTER, 1,2-ETHANEDISULFONATE (2:1)
Common Name English
CARAMIPHEN EDISILATE [MART.]
Common Name English
CARAMIPHEN ETHANEDISULFONATE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29698
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
CFR 21 CFR 520.301
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C76459
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
MERCK INDEX
m3048
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY Merck Index
SMS_ID
100000084850
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID9047835
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
PUBCHEM
517304
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
DRUG BANK
DBSALT001670
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
RXCUI
133053
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY RxNorm
FDA UNII
09TQU5PG95
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
CAS
125-86-0
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
EVMPD
SUB01036MIG
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-759-0
Created by admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
PRIMARY